Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Potential Hepatoprotective Effects of Irbesartan, an Accessible Angiotensin II Receptor Blocker, Against Cisplatin-Induced Liver Injury in a Rat Model.

Autor: ERTUNÇ, Onur¹ (AUTHOR), ERZURUMLU, Yalçın² (AUTHOR), SAVRAN, Mehtap³ (AUTHOR), ÇATAKLI, Deniz³ (AUTHOR), KIRAN, Eltaf DOĞAN⁴ (AUTHOR), PEKGÖZ, Şakir¹ (AUTHOR)

Publikováno v: Turkish Journal of Pharmaceutical Sciences. Apr2024, Vol. 21 Issue 2, p88-94. 7p.

A Five-Year Prospective, Randomized, Open-Label Study of Standard-Dose Versus Low-Dose Prolonged-Release Tacrolimus With or Without Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker Post Kidney Transplantation.

Autor: Campbell PM; Department of Laboratory Medicine and Pathology, University of Alberta Hospitals, Edmonton, Alberta, Canada., Cantarovich M; Division of Nephrology, Department of Medicine, McGill University Health Centre, Montréal, Québec, Canada., Gangji A; Department of Medicine, St Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada., Houde I; Department of Medicine, L'Hôtel-Dieu de Québec, Québec City, Québec, Canada., Jevnikar AM; Department of Internal Medicine, London Health Sciences Centre, London, Ontario, Canada., Monroy-Cuadros FM; Division of Transplant Surgery, Foothills Medical Centre, Calgary, Alberta, Canada., Nickerson PW; Department of Internal Medicine and Immunology, Health Sciences Centre, Winnipeg, Manitoba, Canada., Pâquet MR; Division of Nephrology, Hôpital Notre-Dame du CHUM, Montréal, Québec, Canada., Prasad GVR; Division of Nephrology, St Michael's Hospital, Toronto, Ontario, Canada., Senécal L; Department of Medicine, Hôpital Maisonneuve-Rosemont, Montréal, Québec, Canada., Wolff JL; Department of Medicine, Centre Hospitalier Universitaire, Sherbrooke, Québec, Canada., Schwartz JJ; Medical Affairs, Astellas Pharma Global Development, Northbrook, Illinois, USA., Rush DN; Department of Internal Medicine and Immunology, Health Sciences Centre, Winnipeg, Manitoba, Canada.

Publikováno v: Clinical transplantation [Clin Transplant] 2025 Jan; Vol. 39 (1), pp. e70067.

Structural studies identify angiotensin II receptor blocker-like compounds as branched-chain ketoacid dehydrogenase kinase inhibitors

Autor: Liu, Shenping, Kormos, Bethany L., Knafels, John D., Sahasrabudhe, Parag V., Rosado, Amy, Sommese, Ruth F., Reyes, Allan R., Ward, Jessica, Roth Flach, Rachel J., Wang, Xiaochun, Buzon, Leanne M., Reese, Matthew R., Bhattacharya, Samit K., Omoto, Kiyoyuki, Filipski, Kevin J.

Publikováno v: In Journal of Biological Chemistry March 2023 299(3)

The use of angiotensin II receptor blocker is associated with greater recovery of cardiac function than angiotensin‐converting enzyme inhibitor in dilated cardiomyopathy

Autor: Nobuyuki Enzan, Shouji Matsushima, Tomomi Ide, Takeshi Tohyama, Kouta Funakoshi, Taiki Higo, Hiroyuki Tsutsui

Publikováno v: ESC Heart Failure, Vol 9, Iss 2, Pp 1175-1185 (2022)

Abstract Aims Angiotensin‐converting enzyme inhibitors (ACEis) or angiotensin II receptor blockers (ARBs) have been shown to be associated with recovery of cardiac function in patients with dilated cardiomyopathy (DCM). The aim of this study was to

Externí odkaz: https://doaj.org/article/bfa41432e09a442b9da5655b7c71fb96